Profile
| Metric | Value |
|---|---|
| Full Name | DexCom, Inc. |
| Ticker | NASDAQ: DXCM |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Country | United States |
| IPO | |
| Indexes | |
| Website | dexcom.com |
| Employees | 10,200 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $70.25 | |
| Price, 1D Change | -1.03% | |
| Market Cap | $27B | |
| - | ||
| PE Ratio | 39.10 | |
| Beta | 1.02 | |
| Revenue | $4B | |
| Revenue, 1Y Change | +11.34% | |
| EPS | $1.42 | |
| EPS, 1Y Change | +9.35% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 4:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.42 | |
| EPS Estimate | $2.06 | |
| EPS Est. Change | +44.89% | |
| Revenue | $4.03B | |
| Revenue Estimate | $4.64B | |
| Revenue Est. Change | +15.16% | |
| Current Price | $70.25 | |
| Price Target | - | $84.50 |
| Price Tgt. Change | - | +20.28% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.44 | $1.30 | -9.57% | |
| $1.69 | $1.42 | -15.54% | |
| $2.06 | N/A | +44.89% | |
| $2.48 | N/A | +73.90% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $3.60B | $3.62B | +0.54% | |
| $4.02B | $4.03B | +0.25% | |
| $4.64B | N/A | +15.16% | |
| $5.23B | N/A | +29.76% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -11.27% | |
| Price, 3Y | -35.24% | |
| Market Cap, 1Y | -11.42% | |
| Market Cap, 3Y | -34.61% | |
| Revenue, 1Y | +11.34% | |
| Revenue, 3Y | +64.71% | |
| EPS, 1Y | +9.35% | |
| EPS, 3Y | +181.53% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $70.25 | |
| SMA 200 | $73.75 | |
| SMA 200 vs Price | +4.98% | |
| SMA 50 | $63.99 | |
| SMA 50 vs Price | -8.91% | |
| Beta | 1.02 | |
| ATR | $2.33 | |
| 14-Day RSI | 61.15 | |
| 10-Day Volatility | 37.68% | |
| 1-Year Volatility | 45.10% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $4.03B | |
| EPS | $1.42 | |
| Gross Profit | $2.43B | |
| Gross Margin | 60.29% | |
| Operating Profit | $600.00M | |
| Operating Margin | 14.88% | |
| Net Income | $576.20M | |
| Net Margin | 14.29% | |
| EBITDA | $600.00M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 1.23 | |
| Current Ratio | 1.47 | |
| Quick Ratio | 1.28 | |
| - | ||
| F-Score | 8 | |
| Altman Z-Score | 5.28 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 39.10 | |
| PS Ratio | 6.07 | |
| PB Ratio | 10.05 | |
| EV/EBITDA | 26.08 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $2.10B | |
| Cash & Equivalents | $2.58B | |
| Total Assets | $6.48B | |
| Current Assets | $4.30B | |
| Total Liabilities | $4.38B | |
| Current Liabilities | $2.93B | |
| Total Debt | $2.59B | |
| Short Term Debt | $1.23B | |
| Accounts Payable | $345.30M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $3.43B | |
| Operating Expenses | $1.84B | |
| Cost Of Goods Sold | $1.60B | |
| SG&A | $0.00 | |
| D&A | $217.70M | |
| Interest Expense | $0.00 | |
| Income Tax | $132.80M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $989.50M | |
| CFI | -$207.50M | |
| CFF | -$734.80M | |
| Capex | $358.80M | |
| Free Cash Flow | $630.70M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Bernstein | → | |
| Mizuho | → | |
| Citigroup | → | |
| Morgan Stanley | → | |
| Evercore ISI Group | ||
| Morgan Stanley | → | |
| Argus Research | → | |
| UBS | → | |
| Truist Securities | → | |
| Barclays | → |
Analyst sentiment
Institutional ownership
Screeners with DXCM
Data Sources & References
- DXCM Official Website www.dexcom.com/global
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1093557/000109355725000280/0001093557-25-000280-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- List of NASDAQ 100 Companies www.nasdaq.com/market-activity/quotes/nasdaq-ndx-index
- DXCM Profile on Yahoo Finance finance.yahoo.com/quote/DXCM
- DXCM Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/dxcm
FAQ
What is the ticker symbol for DexCom, Inc.?
The ticker symbol for DexCom, Inc. is NASDAQ:DXCM
Does DexCom, Inc. pay dividends?
No, DexCom, Inc. does not pay dividends
What sector is DexCom, Inc. in?
DexCom, Inc. is in the Healthcare sector
What industry is DexCom, Inc. in?
DexCom, Inc. is in the Medical Devices industry
What country is DexCom, Inc. based in?
DexCom, Inc. is headquartered in United States
When did DexCom, Inc. go public?
DexCom, Inc. initial public offering (IPO) was on April 14, 2005
Is DexCom, Inc. in the S&P 500?
Yes, DexCom, Inc. is included in the S&P 500 index
Is DexCom, Inc. in the NASDAQ 100?
Yes, DexCom, Inc. is included in the NASDAQ 100 index
Is DexCom, Inc. in the Dow Jones?
No, DexCom, Inc. is not included in the Dow Jones index
When was DexCom, Inc. last earnings report?
DexCom, Inc.'s most recent earnings report was on October 30, 2025
When does DexCom, Inc. report earnings?
The next expected earnings date for DexCom, Inc. is February 12, 2026